Interstitial Lung Diseases clinical trials

Explore recruiting interstitial lung diseases clinical trials.

Recruiting interstitial lung diseases studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Interstitial Lung Diseases trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Palliation of Dyspnea and Cough using Morphine in patients with Fibrotic Interstitial Lung Disease

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

Assessment of the effect of Wharton's jelly mesenchymal stem cell preparation (WJMSCs) in the treatment of fibrotic interstitial lung diseases

Poland

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary Fibrosis

Netherlands, Czechia, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

Netherlands, Greece, Slovenia, Germany, Hungary, France +13 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Hyperpolarized 129-Xenon MRI in Fibrosing Interstitial Lung Disease

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over at least 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD)

Netherlands, Germany, France, Spain, Italy, Austria +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Interstitial Lung Diseases trials by city

Interstitial Lung Diseases in Toronto Interstitial Lung Diseases in Vancouver Interstitial Lung Diseases in Montreal Interstitial Lung Diseases in Calgary Interstitial Lung Diseases in Edmonton Interstitial Lung Diseases in Ottawa Interstitial Lung Diseases in Winnipeg Interstitial Lung Diseases in Quebec City Interstitial Lung Diseases in Hamilton Interstitial Lung Diseases in Kitchener Interstitial Lung Diseases in London Interstitial Lung Diseases in Halifax Interstitial Lung Diseases in New York Interstitial Lung Diseases in Los Angeles Interstitial Lung Diseases in Chicago Interstitial Lung Diseases in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease